What You Should Know:
- CancerIQ, a Chicago-based platform powering early cancer detection and prevention across broad patient populations, announced today it closed a $14M Series B financing round.
- The Series B round was co-led by Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures with participation from McKesson Ventures, OSF Ventures (the investment arm of OSF HealthCare, a current CancerIQ customer), and HealthX Ventures.
Inequality in
Read More
Oncology Platform
Jasper Health Raises $25M for Cancer Care Navigation and Experience Platform
What You Should Know:
- Jasper Health, an NYC-based cancer care coordination and experience platform raise $25M in Series A funding led by General Catalyst.
- The round, which was joined by new and existing investors Human Capital, W Health Ventures, Redesign Health, and 7wireVentures, brings Jasper’s total funding to approximately $31 million.
End-to-End Oncology Solution
1.8 million people are diagnosed with cancer every year. It’s an emotional and complicated process that no one
Read More
Syapse, Pfizer Extends Collaboration to Generate Real-World Evidence in Breast Cancer
What You Should Know:
- Syapse, a real-world evidence company that informs cancer care, announced that it will extend its collaboration with Pfizer to generate real-world evidence in breast cancer.
- This is the third phase of the collaboration, which was first announced in 2019 and renewed in 2021.
Generate Real-World Evidence in Breast Cancer
As part of the next phase of the collaboration, Syapse will provide insights and services to Pfizer, using the Syapse Learning Health Network
Read More
Illumina and Syapse Partner on Biomarker Testing Research Across Oncology Practices
What You Should Know:
- Syapse, a real-world evidence company that informs cancer care, announced a partnership with Illumina aimed at assessing the real-world uptake and actionability of comprehensive genomic profiling in the community oncology health system setting.
- Together, the two companies will work to better understand biomarker testing patterns among clinicians, which have become foundational in identifying treatment options for cancer patients. The insights gleaned from this
Read More
Bayhealth Taps Syapse’s Real-World Data Platform to Optimize Oncology Data
What You Should Know:
- Syapse, a real-world evidence company that informs cancer care, announced a partnership with Bayhealth – central and southern Delaware’s largest healthcare system.
- Bayhealth will leverage Syapse’ multi-source real-world data platform to bring the latest in cancer diagnostics and treatments to Delaware patients, so that they can receive evidence-based care and match to potentially life-saving clinical trial opportunities.
Bringing Data-Driven Approach to
Read More
NeoGenomics Acquires Precision Oncology Platform Trapelo Health for $65M
What You Should Know:
- NeoGenomics, Inc., a provider of cancer-focused genetic testing services and global oncology contract research services announced it has reached an agreement to acquire precision oncology platform Trapelo Health for $65M. The agreement purchase price of $65 million, consists of $35 million in cash on hand and $30 million in NeoGenomics common stock and is expected to close in April 2021.
- Trapelo Health offers a first-of-its-kind, interoperable, decision-support
Read More
Syapse Lands $68M to Expand Global Precision Oncology Data Sharing Network
What You Should Know:
- Syapse raises 68M in equity investment led by Ally Bridge Group (ABG), with Northpond Ventures to expand delivery of real-world evidence through Syapse’s Learning Health Network.
- The Syapse Learning Health Network is a global precision oncology data sharing network, improving cancer care across communities by using real-world data to support clinical decisions.
Syapse, a San Francisco, CA-based real-world evidence company accelerating the delivery
Read More
COTA Lands $34M to Drive Innovation in Oncology Using Real-World Data
What You Should Know:
- COTA, Inc., a healthcare technology company that uses
real-world data to bring clarity to cancer care, has secured $34M in funding.
- Access to over one million patient data records and additional
funding support enhanced real-world data and analytics services in oncology.
COTA, Inc., a Boston, MA-based healthcare technology company that uses real-world data to bring clarity to cancer care, today announced it has raised $34 million in Series D funding led by
Read More
M&A: RxVantage Acquires onPoint Oncology to Expand Offering to Oncology Practices
What You Should Know:
- RxVantage has acquired onPoint Oncology to provide cancer care teams with on-demand access to educational resources, reimbursement data, and analytics.
- The acquisition of onPoint Oncology builds on
RxVantage’s rapidly expanding digital offerings for providers. In April,
RxVantage launched Virtual Meetings to help providers reestablish access to
life science experts amidst the disruptions caused by COVID-19.
RxVantage, the
leading digital
Read More
CancerIQ Raises $5M to Expand Genetic Cancer Risk Assessment Platform
What You Should Know:
- CancerIQ raises $5M in Series A funding led by HealthXVentures to accelerate the growth of its genetic cancer risk assessment platform to identify and manage patients at high risk of cancer.
- CancerIQ’s technology enables hospitals to use genomics
to personalize the prevention and early detection of cancer.
- Two new hires recently joined CancerIQ’s newly formed
Integrated Products team from Epic, with the goal of advancing CancerIQ’s
integration with leading
Read More
